Continuity Biosciences and Breakthrough T1D Collaborate to Advance NICHE® Cell-Therapy Platform Toward First-in-Human Study

Contributed by: PR Newswire

Images

PR Newswire associated0

PR Newswire associated1

Tags

ContinuityBiosciences

More Like This

PR Newswire associated0

Continuity Biosciences Launches to Enable Breakthrough Therapies with Innovative Delivery Technologies

PR Newswire associated0

Continuity Biosciences Announces First-in-Human Clinical Trial of Precision Drug Delivery Platform for Pancreatic Cancer

Diamyd Medical announces expanded financial support from Breakthrough T1D

PR Newswire associated0

Continuity Biosciences Acquires Focal Medical to Advance Targeted Drug Delivery for Pancreatic Cancer

From Biopsy to Breakthrough, CTIBIOTECH USA™'s Vision for Precision Medicine

Printing the Future of Medicine: CTIBIOTECH™ Announces $27 Million Investment to Launch U.S. Operations at the SelectUSA Investment Summit

One Biosciences Receives €3,3 Million Funding Under i-Démo 5 From France 2030 to Accelerate Development of First Single-Cell Diagnostic for Triple-Negative Breast Cancer, in Collaboration With Institut Curie

PR Newswire associated0

NueCell Bio Announces its Launch as a New Translational Partner for Cell Therapies with Unique Expertise to Accelerate Treatments from Discovery into GMP Manufacturing

PR Newswire associated0

Metabolon Receives NIH Grant to Develop Advanced Monitoring and Predictive Tools for Type 1 Diabetes Progression